254 related articles for article (PubMed ID: 28141684)
1. Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer.
Ibrahim EY; Busaidy NL
Curr Opin Oncol; 2017 Mar; 29(2):151-158. PubMed ID: 28141684
[TBL] [Abstract][Full Text] [Related]
2. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.
Dadu R; Cabanillas ME
Minerva Endocrinol; 2012 Dec; 37(4):335-56. PubMed ID: 23235190
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
[TBL] [Abstract][Full Text] [Related]
4. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
Gosain R; Alexander JS; Gill A; Perez C
Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
[TBL] [Abstract][Full Text] [Related]
5. Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.
Zhang L; Li Z; Zhang M; Zou H; Bai Y; Liu Y; Lv J; Lv L; Liu P; Deng Z; Liu C
Med Oncol; 2023 Jul; 40(9):258. PubMed ID: 37524925
[TBL] [Abstract][Full Text] [Related]
6. Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI).
Capdevila J; Galofré JC; Grande E; Zafón Llopis C; Ramón Y Cajal Asensio T; Navarro González E; Jiménez-Fonseca P; Santamaría Sandi J; Gómez Sáez JM; Riesco Eizaguirre G
Clin Transl Oncol; 2017 Mar; 19(3):279-287. PubMed ID: 27704399
[TBL] [Abstract][Full Text] [Related]
7. Redifferentiating agents in non-radioiodine avid cancer.
Seregni E; Vellani C; Castellani MR; Maccauro M; Pallotti F; Scaramellini G; Guzzo M; Greco A
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):513-9. PubMed ID: 19910904
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.
Costa R; Carneiro BA; Chandra S; Pai SG; Chae YK; Kaplan JB; Garrett HB; Agulnik M; Kopp PA; Giles FJ
Drug Des Devel Ther; 2016; 10():873-84. PubMed ID: 27013865
[TBL] [Abstract][Full Text] [Related]
9. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Schechter RB; Nagilla M; Joseph L; Reddy P; Khattri A; Watson S; Locati LD; Licitra L; Greco A; Pelosi G; Carcangiu ML; Lingen MW; Seiwert TY; Cohen EE
Cancer Lett; 2015 Apr; 359(2):269-74. PubMed ID: 25641339
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT; Cohen EE
Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
[TBL] [Abstract][Full Text] [Related]
11. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.
Capdevila J; Newbold K; Licitra L; Popovtzer A; Moreso F; Zamorano J; Kreissl M; Aller J; Grande E
Cancer Treat Rev; 2018 Sep; 69():164-176. PubMed ID: 30032061
[TBL] [Abstract][Full Text] [Related]
12. Update on thyroid cancer treatment.
Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
[TBL] [Abstract][Full Text] [Related]
13. Target therapies for radioiodine refractory advanced thyroid tumors.
Schlumberger M
J Endocrinol Invest; 2012; 35(6 Suppl):40-4. PubMed ID: 23014073
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy in radioiodine refractory thyroid cancer.
Pacini F; Brilli L; Marchisotta S
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):520-5. PubMed ID: 19910905
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies in advanced differentiated thyroid cancer.
Carneiro RM; Carneiro BA; Agulnik M; Kopp PA; Giles FJ
Cancer Treat Rev; 2015 Sep; 41(8):690-8. PubMed ID: 26105190
[TBL] [Abstract][Full Text] [Related]
16. Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.
Fullmer T; Cabanillas ME; Zafereo M
Front Endocrinol (Lausanne); 2021; 12():720723. PubMed ID: 34335481
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
18. The Treatment of Well-Differentiated Thyroid Carcinoma.
Paschke R; Lincke T; Müller SP; Kreissl MC; Dralle H; Fassnacht M
Dtsch Arztebl Int; 2015 Jun; 112(26):452-8. PubMed ID: 26205749
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
Wassermann J; Bernier MO; Spano JP; Lepoutre-Lussey C; Buffet C; Simon JM; Ménégaux F; Tissier F; Leban M; Leenhardt L
Oncologist; 2016 Jan; 21(1):50-8. PubMed ID: 26675742
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine therapy of advanced differentiated thyroid cancer: clinical considerations and multidisciplinary approach.
Giovanella L; Scappaticcio L
Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):229-234. PubMed ID: 31271270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]